KRAS and non-small cell lung carcinoma: Recently, major advances have been made toward the development of drugs that target tumors that harbor mt KRAS G12C with two inhibitors, sotorasib and adagrasib, FDA approved for patients with advanced NSCLC harboring KRAS G12C mutation (14–17, 22, 23, 45).